Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors arising from the gastrointestinal tract, with the jejunum being an uncommon site [1][2]. Surgical resection remains the cornerstone of treatment [2], but postoperative complications can present diagnostic and therapeutic challenges. This report describes a rare postoperative complication gastroparesis following resection of a jejunal GIST.

Patient History

A 43-year-old female presented to Khmer-Soviet Friendship Hospital on February 17, 2025, for follow-up after completion of treatment for right-sided breast cancer. Her prior therapy included a right mastectomy, six cycles of chemotherapy, and 15 sessions of radiotherapy, completed in 2023.

As part of routine oncologic surveillance, a contrast-enhanced abdominal CT scan was performed on February 15, 2025, which revealed a suspicious mass in the abdominal cavity. She was referred to the Thoracoabdominal Surgery Department for further evaluation. On presentation, she reported abdominal discomfort, asthenia, and fatigue. Physical examination revealed a palpable mass in the epigastric region without signs of hepatomegaly or lymphadenopathy.

Imaging and Diagnosis

Ultrasonography revealed a 52 × 42 mm hypoechoic mass in the pancreatic body and tail region, with bilateral nephrocalcinosis.Contrast-enhanced CT scan identified a well-defined hypodense lesion (53 × 46 × 57 mm) with heterogeneous enhancement, originating from the jejunal wall and abutting the pancreatic tail. Vascular supply was noted from the superior mesenteric and gastroduodenal arteries. No evidence of pancreatic origin was found. Additional findings included bilateral ovarian vein dilation and a simple left renal cortical cyst (Figure 1).

Figure 1. (a) and (b): Jejunal Tumor (arrow): A well-defined, hypodense lesion arising from the jejunal wall, closely abutting the tail of the pancreas.

Surgical ManagementFirst Surgery (February 25, 2025):

Laparotomy revealed a 5 × 5 cm tumor at the duodenojejunal (DJ) junction, extending into the Meso-jejunum and retroperitoneum. Following mobilization of the ligament of Treitz, an en bloc resection was performed. Primary duodenojejunal anastomosis was completed to re-establish continuity (Figure 2).

Postoperative Course and Second Operation Postoperative Day 2 (POD 2): The patient developed nausea, vomiting, and mild abdominal distension. Laboratory investigations showed: Elevated CRP: 192.4 mg/L, Leukocytosis: 22.8 K/µL, Electrolytes: Within normal limits.

Table 1.Laboratory findings.

Figure 2. The specimen removed from the surgical field.

Laboratory Findings(Table 1)

Electrolyte disturbances: Hypokalemia (as low as 2.07 mmol/L), hyponatremia, hypochloremiaInflammation: Elevated CRP, leukocytosisAnemia: Hemoglobin dropped from 15.3 g/dL to 9.4 g/dLRenal markers: Elevated urea and creatinineNutritional markers: Hypoalbuminemia, hypoglycemiaSerology:HBsAg positive indicating infection with hepatitis B virus (HBV).

ChestX-rayPreoperative showing a prominent single large air-fluid level suggestive of gastric dilatation, with a markedly distended stomach filled with air, fluid and retained food content.

Abdominal X-ray demonstrating the “double bubble” sign characterized by two distinct air-filled structures one in the stomach and the other in the duodenum with absence of distal bowel gas, suggestive of proximal gastrointestinal obstruction. Based on clinical and radiologic findings, re-exploration was performed on March 10, 2025 (Figure 3).

Figure 3.(a) Chest X-ray (arrow): Shows a single large air-fluid level, suggestive of gastric dilatation. (b) Abdominal X-ray: Demonstrates the “double bubble” sign. two distinct air-filled bubbles, with the red arrow indicating the stomach and the yellow arrow indicating the duodenum with absence of distal bowel gas.

Intraoperative Findings: No evidence of adhesions, anastomosis leakage or stenosis was noted. Marked gastric dilation was present, and a diagnosis of gastroparesis was made.

Second Procedure: A gastrojejunostomy was performed by creating a bypass anastomosis 40 cm distal to the duodenojejunal junction to facilitate gastric emptying.

Histopathological Examination

Histopathological examination of the resected jejunal mass revealed a gastrointestinal stromal tumor (GIST), spindle cell type, measuring 6.5 × 4.5 × 4.5 cm, arising from the submucosal layer. Microscopically, the tumor was composed of spindle-shaped cells with eosinophilic cytoplasm, associated with skeinoid fibers and moderate nuclear atypia, and demonstrated a mitotic index of 4 mitoses per 5 mm². The overlying mucosa was unremarkable, and the surgical resection margins were free of tumor (R0 resection).

Immunohistochemical staining showed strong diffuse positivity for CD117 (c-KIT) and DOG-1, with patchy positivity for smooth muscle actin (SMA) and negative staining for cytokeratin, confirming the diagnosis of gastrointestinal stromal tumor. Based on the tumor size and mitotic activity, the lesion was classified as an intermediate-risk GIST (Figures 4(a)-(h)).

Figure 4. (a) and (b) DOG-1: Demonstrate diffuse and strong membranous and cytoplasmic positivity in the tumor cells; (c) The tumor cells are negative for mucosal epithelial markers (Cytokeratin), which highlight only the normal colonic epithelium; (d) H and E: Sections show colonic mucosa on the surface with preserved glandular architecture. Beneath the mucosa, the tumor is composed predominantly of interlacing fascicles and whorled bundles of uniform spindle cells set within a collagenous stroma; (e) and (f) CD117 (c-KIT): Demonstrate strong diffuse cytoplasmic and membranous positivity in the tumor cells; (g) and (h) Patchy cytoplasmic positivity for Smooth Muscle Actin (SMA) in the tumor cells.

Diagnosis:

Based on the tumor size (>5 cm) and mitotic index (<5 per 5 mm²), the tumor was classified as an Intermediate-Risk Gastrointestinal Stromal Tumor (GIST) according to risk stratification criteria.According to AJCC 8th Edition staging, the tumor corresponds to pT3 N0 M0, corresponding to Stage II disease for small intestinal GIST.

Discharge and follow-up

After the second surgery (gastrojejunostomy), the patient’s diet was started on postoperative day (POD) 3, and she was discharged on POD 9. Adjuvant therapy with imatinib was prescribed for 3 years, as this is the standard treatment for patients with significant risk of relapse. Follow-up included abdominal ultrasonography at 1 week, followed by contrast-enhanced CT scans at 6, 12, and 18 months to monitor for recurrence. Given the intermediate-risk features (small bowel location, tumor size > 5 cm) and the patient’s overall clinical profile, the oncology team recommended imatinib with clinical follow-up every 3 months.

This case illustrates the importance of a multidisciplinary approach in managing GISTs. Early diagnosis through imaging, accurate histopathological assessment, appropriate surgical management, and individualized adjuvant therapy are critical for optimal outcomes. Additionally, rare postoperative complications such as gastroparesis should be recognized promptly and managed effectively to reduce morbidity.